The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...

Novo Nordisk A/S is planning a large study of its next-generation obesity shot CagriSema in children, a sign the drugmaker is pressing forward with the compound despite disappointing results in other ...

Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently updated its clinical study titled ...

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Shortly after, Novo Nordisk's CEO Mike Doustdar signaled the company is "all in" on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...

Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...